Table 1 Patient characteristics
From: Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis
IPF | COPD | Control | p-value | p-value | p-value | |
|---|---|---|---|---|---|---|
(n = 57) | (n = 20) | (n = 15) | IPF vs. Control | IPF vs. COPD | COPD vs. Control | |
Age, years | 69.4 ± 8.5 | 70.8 ± 7.1 | 65.9 ± 7.9 | NS | NS | NS |
Gender, male | 51 (89.5) | 19 (95.0) | 15 (100) | NS | NS | NS |
Current or former smoker | 53 (93.0) | 20 (100) | 7 (46.7) | <0.001 | NS | <0.001 |
Patients who underwent BAL | 25 (43.9) | – | – | |||
Patients who underwent SLB | 10 (17.5) | – | – | |||
FVC, % predicted | 84.2 ± 21.3 | 93.5 ± 20.1 | – | NS | ||
DLCO, % predicted | 43.7 ± 14.2 | 56.6 ± 17.5 | – | 0.004 | ||
6MWD, m | 454 ± 108 | – | – | |||
Minimum SpO2 during 6MWT, % | 85.7 ± 8.4 | – | – | |||
PaO2 at room air, Torr | 82.6 ± 13.1 | – | – |